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Background: Tuberculosis remains the leading cause of death in South Africa. A number of potential new TB
vaccine candidates have been identified and are currently in clinical trials. One such candidate is MVA85A. This
study aimed to estimate the cost-effectiveness of adding the MVA85A vaccine as a booster to the BCG vaccine
in children from the perspective of the South African government.
Methods: The cost-effectiveness was assessed by employing Decision Analytic Modelling, through the use of a
Markov model. The model compared the existing strategy of BCG vaccination to a new strategy in which infants
receive BCG and a booster vaccine, MVA85A, at 4 months of age. The costs and outcomes of the two strategies are
estimated through modelling the vaccination of a hypothetical cohort of newborns and following them from birth
through to 10 years of age, employing 6-monthly cycles.
Results: The results of the cost-effectiveness analysis indicate that the MVA85A strategy is both more costly and
more effective – there are fewer TB cases and deaths from TB than BCG alone. The South African government
would need to spend an additional USD 1,105 for every additional TB case averted and USD 284,017 for every
additional TB death averted. The threshold analysis shows that, if the efficacy of the MVA85A vaccine was 41.3%
(instead of the current efficacy of 17.3%), the two strategies would have the same cost but more cases of TB and
more deaths from TB would be prevented by adding the MVA85A vaccine to the BCG vaccine. In this case, the
government chould consider the MVA85A strategy.
Conclusions: At the current level of efficacy, the MVA85A vaccine is neither effective nor cost-effective and,
therefore, not a good use of limited resources. Nevertheless, this study contributes to developing a standardized
Markov model, which could be used, in the future, to estimate the potential cost-effectiveness of new TB vaccines
compared to the BCG vaccine, in children between the ages of 0–10 years. It also provides an indicative threshold
of vaccine efficacy, which could guide future development.
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BCG vaccineBackground
Tuberculosis (TB) remains the leading cause of death in
South Africa with 62,827 deaths (11.6%) in 2010 [1].
South Africa is one of twenty-two high TB burden coun-
tries and one of twenty-seven high MDR-TB burden
countries. TB/HIV co-infection is also very high, with an* Correspondence: Edina.Sinanovic@uct.ac.za
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article, unless otherwise stated.estimated 0.5 million new TB cases, of which 65% were
in HIV positive individuals [2].
Globally, TB in children remains a neglected priority
of stakeholders, including researchers, governments, and
policy makers. It is only recently that policy makers and
advocates have begun raising the issues around addressing
childhood diseases, including child-friendly medicine for-
mulations and diagnostics and ensuring that data relevant
to children are available. For this reason, the true extent of
the global burden of TB disease in children is not knowned Central Ltd. This is an Open Access article distributed under the terms of
tp://creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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64,000 deaths, annually [2]. Although, proportionally,
these numbers are small compared to adolescents and
adults, the morbidity and mortality in children tends
to be higher as children tend to acquire the more se-
vere forms of TB and treatment may be delayed given
the difficulties in diagnosing TB in children. Furthermore,
once infected, children become the reservoir for future TB
disease [5].
Data on the burden of TB in children in South Africa
is inadequate. The limited information available suggests
that childhood TB represents about 15-20% of TB dis-
ease burden in South Africa [7]. Mortality data shows
that TB is the 5th leading cause of death in all children
under 14 years, the 6th leading cause in the post-neonatal
period (age 29 days to 11 months), and the 4th leading
cause in children 1-4 years [1].
The Bacille Calmette-Guérin (BCG) vaccine is, cur-
rently, the only commercially available vaccine against
tuberculosis. Data on its effectiveness in preventing pri-
mary infection and disease progression to pulmonary TB
is highly varied – ranging from 0–80%. However, there
is consensus that BCG is protective against disseminated
forms of TB, including military and meningeal TB
[8-12], and a cost-effectiveness analysis, conducted in
2006, declared BCG vaccination to be “highly cost-
effective” [13]. South Africa introduced universal BCG
vaccination for all infants at birth in 1972 [14].
Modelling studies show that existing strategies alone
are not sufficient to achieve the 2050 target of elimination
of TB as a public health concern, and that new strategies
for prevention (e.g. new tools for diagnosis and new vac-
cines, particularly new vaccines that both prevent infec-
tion and disease progression), and treatment (e.g. shorter,
more effective regimens) are needed [15-17].
Following the successful sequencing of the Mycobac-
terium Tuberculosis (M.tuberculosis) genome as well as
progress in sequencing BCG, a number of potential new
TB vaccine candidates have been identified and are,
currently, in Clinical Trials. One such candidate is
MVA85A. MVA85A is a “post-exposure” sub-unit vaccine
that is designed to boost the immunological response of
BCG [18-20].
Resources for TB control are limited and have been
further constrained due to the global financial crisis. In
addition, a number of new vaccines (e.g. pneumococcal,
rotavirus, and human papillomavirus) have been devel-
oped over the past decade which increases the competi-
tion for these limited resources. Governments and
donors need to determine which interventions or set of
interventions they should invest in so as to have the
greatest impact on their populations’ health.
This study aimed to examine the cost-effectiveness of
adding the MVA85A vaccine as a booster to the BCGvaccine in children from the perspective of the South
African government.
The economic evaluation was requested by the product
developers in 2012 and the study was conceptualized
while the Phase IIb clinical trial in infants was still on-
going. Despite the disappointing results, which were made
available in 2013 [21], we believe that the development of
a model, which could be used to assess the potential cost-
effectiveness of other new TB vaccines in infants, together
with the establishment of a threshold efficacy value con-
tributes to the on-going work in bringing a new TB
vaccine to market; consequently, we proceeded with the
study and with submission for publication.
Methods
Study design
A Markov state transition model was developed in Tree-
Age Pro Suite® 2012 to reflect the natural course of TB
in children. The model compared the existing strategy of
BCG vaccination at birth to a new strategy in which
infants receive BCG at birth and a booster vaccine,
MVA85A, at 4 months of age. The costs and outcomes of
the two strategies were estimated through modelling the
vaccination of a hypothetical cohort of newborn children
and following them from birth through to 10 years of age,
employing 6-monthly cycles. A time horizon of 10 years
was chosen as this represents the time period over which
there is a unique pathway of TB in children. Beyond
10 years, the course of TB tends to mimic that of adults.
Furthermore, data on the effectiveness of the MVA85A
vaccine in adults is not yet known and data on the
effectiveness of the BCG vaccine beyond 10 years is
highly varied. Modelling is employed to estimate the
cost-effectiveness of a new vaccination strategy as it
allows us to extend the costs and outcomes of the
two interventions beyond the trial time-horizon of
2 years.
Model description
Eight mutually exclusive health (Markov) states repre-
senting the natural history of tuberculosis (TB) disease
in children were used (Figure 1). Transitions amongst
health states were permitted according to specific transi-
tion probabilities and specific criteria (Table 1, Figures 1
and 2). Patients could remain in certain health states
(e.g. uninfected) and “Death” was considered to be an
absorbing state. The model is a static (one Annual
Risk of Infection has been used for the entire duration of
the model), population-based (a single cohort moves
through the model), deterministic (set parameters are
used to determine how the cohort moves through the
model), closed (new individuals cannot enter the model
over the 10-year period), and discrete (events occur


















Figure 1 Health states and possible transitions (State diagram).
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disease states – pulmonary TB (PTB), miliary TB (mTB),
and TB meningitis (TBM), and the risk of death from
these disease states were reflected in the model together
with the risk of TB infection (Table 1). These data have
been taken from the published literature, expert opinion,
and government data bases such as the South African
electronic TB (e-TB) register.
Data on all-cause mortality rates were taken from
WHO 2009 Life-Tables [27] and were adjusted to remove
the age-specific risk of dying from one of three TB disease
states. Once available, data on the efficacy of MVA85A
was taken from the results of the Phase IIb Clinical Trial
in Worcester, South Africa, which showed the efficacy rate
against tuberculosis in infants to be 17.3% [21].
Whilst there is no standardised Markov model for the
evaluation of new TB vaccines, other Markov models
have been developed and used in childhood vaccines
[31-33]. Our model uses the same conceptual framework
like these models i.e. it followed a natural history of
disease, it included several health states and applied an
appropriate time horizon for the study population, and it
made use of all the relevant epidemiological parameters,
vaccine characteristics and costs. The face validity of our
model was established by consulting local experts on
assumptions regarding the natural history of childhood
TB infection, disease and treatment and resulting model
predictions.
Expert opinion was obtained through a meeting of
experts in paediatric TB, TB epidemiology, and TB
vaccine development. The model and parameters, in-
cluding assumptions were presented to the experts andtheir feedback elicited. Follow-up with the experts oc-
curred via e-mail.
The following assumptions were made in our model:
 all children started out uninfected and, once
infected, a child could never be uninfected;
 a single Annual Risk of Infection (ARI) of 3% was
used throughout the duration of the model, for all
age groups, and for both the risk of “TB infection”
and “TB reinfection”;
 three age groups (0–2 years, 3–5 years, and
6–10 years) were represented in the model. These
represented the ages at which the risks associated
with progression to disease and mortality was
significantly different;
 the efficacy of BCG vaccine was indirectly included
in the model by virtue of the fact that the TB data
used in the model has been taken from a setting in
which BCG has been routinely administered since
the 1970’s [14] and up-take – defined as the
proportion of children eligible to receive the
vaccine who actually receive the vaccine – is in
excess of 95% [28];
 the efficacy of BCG remained constant over the
10-year period and BCG did not have a direct
effect on all-cause mortality
 the drop-out rate between the DTP3 vaccine
(given at 14 weeks) and the MCV vaccine
(given at 9 months) [29] was taken as the proxy
for MVA85A vaccine up-takea; and,
 vaccine up-take was used together with efficacy
to calculate the effectiveness.
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Table 1 Model parameters: estimates of the probability





17.3 (12.3 – 22.3)b
Up-take BCG [21]
Up-take MVA85A 99.0 (98.5 – 99.5) [28]
Drop-out rate
DTP3 to MCV
85.0 (76.4 – 89.5) Calculated
Discount
rate_outcomes
14.0 (9.5 – 23.1) [29]
Discount
rate_costs
3 (0 – 6) [30]
3 (0 – 6) [30]
aExpert opinion provided by Professor Willem Hanekom, Dr Mark Hatherill,
Professor Anneke Hesseling, Professor Helen McShane, Dr Hassan Mohammed,
Dr Roxana Rustomjee, and Dr Michele Tameris.
bIn order to assess the sensitivity of the ICER to the vaccine efficacy, we
randomly assigned a range of +/-5% to the clinical trial efficacy of 17.3%.
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herd immunity, as humans seem to have a natural resist-
ance to infection with M.tuberculosis and to progression
to TB disease, which doesn’t appear to be further en-
hanced by the BCG vaccine [17] and is not being studied
for the MVA85A vaccine; (b) isoniazid preventive therapy
(IPT), as the effect would have been equal in both arms;
(c) BCG disseminated disease (a side-effect of BCG vac-
cination), as the effect would have been equal in both
arms; and, (d) although HIV is an important co-infection
in the context of South Africa, it has been excluded from
our model as there is no data on the efficacy of MVA85A
vaccine given with BCG vaccine in HIV positive infants
and, in the Phase IIb study, MVA85A vaccine was not
given to infants who had a positive HIV diagnosis by
4 months. In addition, the TB data used will have
accounted for the increased risk of TB disease due to
HIV status.
Costing methods
Costs were taken from the perspective of the South
African government and were estimated using an
ingredients-based costing methodology. All cost data,
except for the price of MVA85A, was taken from the
raw data collected for a South African study pub-
lished in 2013; the data were collected in 2009 [34].
The costs were inflated using consumer price index
(CPI) figures to 2012 values [35], and then converted
to US dollars (USD) at the average exchange rate
USD to ZAR for 2012 of USD 1 = ZAR 8.12 [36]. The
Oxford Emergent TB Consortium (OETC) provided
the price of MVA85A vaccine in USD. All costs were
Figure 2 One arm of the Markov model (BCG + MVA85A).
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and treatment are reflected in Table 2 with details pro-
vided in Additional file 1.Effectiveness and cost-effectiveness measurement
As the vaccine was designed to prevent progression
from TB infection to TB disease, we calculated the abso-
lute difference in the number of TB cases and TB deaths
between the two alternatives. This was achieved through
using transition rewards rather than state/incremental
rewards. Given that very limited information is available
on the utilities associated with the various health states
for TB in children, as well as the difficulty in determin-
ing these, the Quality-Adjusted Life-Years (QALY) were
not used. Likewise, given the controversies around age
weighting through welfare interdependence and disabil-
ity weighting particularly in children, the Disability Ad-
justed Life-Year (DALY) approach was not considered.
The model was designed to determine the number of
TB cases averted and the number of TB deaths averted.
At the end of the 10-year period the cumulative costs
and outcomes of each intervention were used to calcu-
late the cost-effectiveness ratio (CER) (i.e. the cost per
TB case averted and the cost per TB death averted) for
each intervention. These two cost-effectiveness ratios
were compared using an incremental cost-effectiveness
ratio (ICER), which represent the additional cost per
additional benefit received.
Consistent with recommendations, all future costs and
outcomes were discounted at 3% per annum [30].
Dealing with uncertainty
By its very nature modelling is considered subjective and
involves a degree of uncertainty [37]. We, therefore,
conducted a univariate sensitivity analysis to check for
uncertainty around the discount rate, MVA85A vaccine
efficacy, vaccine cost, vaccine coverage, and annual risk
of infection. To determine the relationship between the
cost and efficacy of the MVA85A vaccine, we conducted
a bivariate sensitivity analysis (Figure 3). A threshold
analysis was performed to determine the level of efficacy
at which the cost of the MVA85A vaccine strategy would
equal the cost of the BCG strategy, but produce add-
itional benefits.
Results
We acknowledge that a cost-effectiveness analysis would
not traditionally be carried out on an ineffective inter-
vention. Nevertheless, given that the model was devel-
oped while the efficacy study was still on-going, we ran
the model with the study outcome of 17.3%. Table 3
shows the discounted and undiscounted 10-year costs,
the absolute number of TB cases and TB deaths, and in-
cremental cost-effectiveness ratios (ICERs) associated
with adding MVA85A vaccine to the existing strategy of
BCG at birth, from the perspective of the South African
government. Both the discounted and undiscounted re-
sults show that adding the MVA85A vaccine to the BCG
Table 2 Cost of vaccination, diagnosis and treatmenta in 2012 USD: base-case estimates and source
Parameters Value Range References
Cost of BCG vaccination (USD 2012)b 13.57 13.43 – 14.28 [34-36] and personal communication (Arnot, Hayes)d
Cost of MVA85A vaccination (USD 2012)c 28.22 20.22 – 48.22
[34-36] and personal communication (Oxford Emergent
Tuberculosis Consortium (OETC))
Costs of diagnosis & treatment PTB (USD 2012) [34-36]
0-2 years 406.13
[34-36] and personal communication (Arnot, Hayes, von Zeil)d
3-5 years 433.13
6-10 years 459.29








aTB treatment costs: an average weight of 10kg was used for the age group 0-2 years, 20kg for 3-5 years, and 30kg for 6-10 years. As per the South African TB
guidelines treatment is given daily (7 days a week) for 6 months (2 months intensive phase and 4 months continuation phase) for pulmonary TB and miliary TB;
whereas treatment is given daily for 6-9 months (single phase of treatment) for TB meningitis. Other costs include costs associated with various diagnostics and
laboratory monitoring as well as hospital and clinic costs.
bThe cost of BCG vaccine includes the cost per dose, which includes 40% wastage, the cost for a needle and syringe, and the cost of a clinic visit.
cThe cost of MVA85A vaccine includes the cost per dose (provided by OETC), the cost for a needle and syringe, and the cost of a clinic visit.
dProvided information on South African tender award for TB medicines and BCG vaccine as well as wastage rates for BCG vaccine.
Figure 3 Bivariate analysis of the cost and the efficacy of the MVA85A vaccine.
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Table 3 Cost-effectiveness of adding the MVA85A vaccine to the BCG vaccine, in 2012 USD
Strategy




ICER per TB case
averted (USD 2012)
ICER per TB deaths
averted (USD 2012)(USD 2012)
Discounted (3%)
BCG alone 84.17 0.09101 0.0003501817
plus MVA85A 98.23 0.07828 0.0003006626 1,105 284,017
Undiscounted
BCG alone 97.65 0.10627 0.0004174069
plus MVA85A 109.80 0.09138 0.0003583168 816 205,603
Discounted (6%)
BCG alone 73.53 0.07885 0.0002969804
plus MVA85A 89.10 0.06785 0.0002550313 1,416 371,271
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base-case scenario reveals ICERs of USD 1,105 per TB
case averted and USD 284,017 per TB death averted.
Sensitivity analyses
A summary of the sensitivity analyses for key parameters
is provided in Table 4. The results showed that the out-
comes were robust; being most sensitive to the ARI,
MVA85A vaccine efficacy, and the MVA85A vaccine price.
The bivariate analysis shows that the efficacy of the vac-
cine would need to be significantly greater to justify any
increases in cost and that the ICER to sensitive to bothTable 4 Effect of differing assumptions on the base-case
ICER
Parameter Increase/Decrease inICER (TB cases averted)
Increase/Decrease in
ICER (TB deaths averted)
Annual Risk of
Infection (ARI)
2% + 79.86% + 79.71%
4% - 39.88% - 39.83%
MVA85A vaccine
cost (USD)
20.22 - 48.35% - 48.35%
48.22 + 120.87% + 120.87%
MVA85A vaccine
up-take
76.4% + 0.14% + 0.12%
89.5% - 0.07% - 0.06%
MVA85A vaccine
efficacy
12.3% + 69.90% + 69.81%
22.3% - 38.55% - 38.52%
Discounting
0% -26.15% - 27.61%
6% 28.14% + 30.72%cost and efficacy. The threshold analysis shows that at an
efficacy of 41.3%, the MVA85A vaccine produces more
benefits, but at a cost equal to the BCG vaccine.
Discussion
This study explored the cost-effectiveness of adding the
MVA85A vaccine as a booster to the BCG vaccine in
children from the perspective of the South African gov-
ernment. The recently published results of the Phase IIb
clinical trial conducted in Worcester, South Africa,
showed the efficacy of the MVA85A vaccine in prevent-
ing TB in infants to be 17.3% [21]. The vaccine can,
therefore, be considered ineffective. This has had a no-
ticeable effect on the outcomes of our study. Neverthe-
less, we proceeded for two reasons – the first being the
importance of finalizing the development and testing of
a model, which could potentially be used for assessing
the cost-effectiveness of other new TB vaccine candi-
dates currently being studied; and the second being the
possibility of establishing a threshold value for efficacy
which could guide TB vaccine development. To the best
of our knowledge, there are no other completed clinical
trials or on-going clinical trials evaluating the efficacy of
MVA85A vaccine in infants and this is the only pub-
lished study indicating the efficacy of the vaccine in
infants.
At the cost of USD 1,105 per TB case averted and
USD 284,017 per TB death averted, adding the MVA85A
vaccine as a booster to the BCG vaccine in children not
cost-effective when compared to the cost-effectiveness
of other childhood vaccines. For instance, a study in
Mozambique showed the incremental cost of introdu-
cing hepatitis B vaccine into infant immunization services
to be USD 1,833 per death averted and USD 47 per
DALY averted [38]. A study in Vietnam found routine
immunization with rotavirus vaccine to be cost-effective
at USD 40 per DALY averted [31]. However, comparison
of cost-effectiveness evidence has a number of limitations:
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different price levels and different cost base years.
We developed a Markov model which reflects the
natural course of TB in children and represents 3 sig-
nificant age groups associated with progression to TB
disease and TB mortality in children up to 10 years.
This model could be used to determine the cost-
effectiveness of other new TB vaccines being tested in
infants and could be modified to different country
contexts. In addition, the model could, potentially, be
adapted to reflect the different populations that the
efficacy of MVA85A continues to be tested in (e.g. HIV-
positive adults). Further work would need to be done to
calibrate the model.
The limitations of our study arise from the paucity of
data on childhood TB during the chemotherapy era, and
our inability to access the full South African e-TB
register dataset. For these reasons, parameters have been
derived from the Western Cape’s e-TB register. As the
Western Cape has the third highest number of TB cases
in South Africa [39], we do not believe that this has dis-
torted the results. The study assumed an annual risk of
infection of 3% and has applied this to the e-TB register
data in order to establish the risk of progressing to dis-
ease. It was also assumed that the e-TB register data
reflected the effectiveness of the BCG vaccine in the
population given that the Western Cape has routinely
administered BCG since the 1970’s [14] and up-take is
in excess of 95% [28].
The threshold analysis shows that, if the efficacy of the
MVA85A vaccine was 41.3% (instead of the current
efficacy of 17.3%), the two strategies would have the
same cost but more cases of TB and more deaths from
TB would be prevented by adding the MVA85A vaccine
to the BCG vaccine. This result is consistent with a
recently published study by Ditkowsky and Swartzman
which showed that, at values below 40% efficacy for
MVA85A, the MVA85A booster strategy is more expen-
sive and only slightly more effective than BCG alone
[40]. They are also similar to earlier analyses of novel
vaccines for TB [41,42]. In this case, the South African
government could consider the MVA85A strategy, but
an affordability study would still need to be conducted.
In addition, sensitisation of the regulatory authority
and communities around modestly efficacious vaccines
would need to occur to ensure that the new vaccine is
licensed, authorised for use, and included in the EPI
schedule and that peoples’ confidence in vaccination
programmes is not eroded so that there is sufficient
up-take of the new vaccine.
Conclusions
Our findings indicate that, due to its low efficacy,
adding MVA85A as a booster to BCG against infantand childhood TB is not cost-effective, and, therefore,
not a viable use of limited resources. Nevertheless,
our research contributes to developing a standardized
Markov model, which could be used, in the future, to
estimate the potential cost-effectiveness of new TB vac-
cines compared to the BCG vaccine, in children between
the ages of 0–10 years. It also provides an indicative
threshold of vaccine efficacy, which could guide future
development.
Endnote
aThe second dose of MVA85A vaccine is given at 4-6
months. We, therefore, used the drop-out rate between
DTP3 vaccine – given at 3.5 months – and the MCV
vaccine – given at 9 months – as the proxy for MVA85A
vaccine up-take.
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